Hepatocellular Carcinoma

The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma.

The International Hepato-Pancreato-Biliary Association established consensus guidelines for liver transplantation among patients with nonresectable colorectal liver metastases.

The fibrosis-4 index may be a useful screening method for hepatocellular carcinoma among patients with non-hepatitis B and non-hepatitis C virus, according to research published in BMC Gastroenterology.

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

Transarterial radioembolization was a well-tolerated first-line treatment among patients with hepatocellular carcinoma, according to research presented at the International Liver Congress.

A treatment regimen of low dose VBI-2601 (BRII-179) injections in patients with chronic hepatitis B exhibited positive safety, tolerability and efficacy, according to a poster presented at the International Liver Congress.

Glucose variability was an independent predictor of hepatocellular carcinoma, according to research presented at The International Liver Congress.

Researchers validated a liver cancer risk test algorithm for identifying patients with chronic hepatitis C at low risk for hepatocellular carcinoma, according to a study presented at The Digital International Liver Congress.